CDA | Evidence Driven
CDA | Evidence Driven

nemolizumab

Details

Generic Name:
nemolizumab
Project Status:
Pending
Therapeutic Area:
atopic dermatitis
Manufacturer:
Galderma Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0869-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​For the treatment of moderate-to-severe AD in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, and/or who are refractory to or ineligible for systemic immunosuppressant therapies.
Fee Schedule:
Pending
Indications:
​For the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years and older who are candidates for systemic therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : January 15, 2025